baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

ACER GDR REG.S/5 TA 10/ US0044342055 /

9/16/2024 10:58:06 AM	Chg. +0.700	Volume	Bid10:58:09 AM	Ask10:58:09 AM	High	Low
6.350EUR	+12.39%	0 Turnover: 0.000	5.600Bid Size: 1,600	7.100Ask Size: 1,200	6.350	6.350

TeleTrader 3/31/2022 PC makers cut growth outlook due to Ukraine crisis - report

GlobeNewswire 10/1/2020 Acer Therapeutics to Present at the Virtual BIO Investor Forum Digital

GlobeNewswire 8/25/2020 Acer Therapeutics to Virtually Present at Upcoming Investor Conferences

GlobeNewswire 8/13/2020 Acer Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire 7/8/2020 Acer Therapeutics Announces Administration of ACER-001 in a Fasted State Increased Systemic Exposure...

GlobeNewswire 5/14/2020 Acer Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire 5/11/2020 Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National ...

GlobeNewswire 4/30/2020 Acer Therapeutics Announces Common Stock Purchase Agreement for up to $15 million with Lincoln Park ...

GlobeNewswire 3/18/2020 Acer Receives Formal Dispute Resolution Request (FDRR) Response from FDA’s Office of New Drugs

GlobeNewswire 3/18/2020 Acer Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate...

GlobeNewswire 2/24/2020 Acer Therapeutics Announces ACER-001 for Urea Cycle Disorders Trial Shows Bioequivalence to BUPHENYL...

GlobeNewswire 12/16/2019 Acer Therapeutics Announces Full Enrollment of Part B in ACER-001 Pivotal Bioavailability and Bioequ...

GlobeNewswire 11/13/2019 Acer Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire 10/28/2019 Acer Therapeutics Announces Full Enrollment of Part A in ACER-001 Pivotal Bioavailability and Bioequ...

GlobeNewswire 8/27/2019 Acer Therapeutics to Present at the 21st Annual H.C. Wainwright Global Investment Conference

GlobeNewswire 8/13/2019 Acer Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire 7/25/2019 Acer Therapeutics to Host Conference Call and Webcast to Discuss Update on its Pipeline Programs

GlobeNewswire 7/5/2019 Acer Therapeutics Announces Restructuring and Update on Pipeline Programs

GlobeNewswire 6/25/2019 Acer Therapeutics Receives Complete Response Letter from U.S. FDA for use of EDSIVO™ (celiprolol) in...

GlobeNewswire 5/31/2019 Acer Therapeutics Announces Poster Presentation at Society for Vascular Medicine Annual Meeting

GlobeNewswire 5/23/2019 Acer Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire 5/14/2019 Acer Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire 5/7/2019 Acer Therapeutics to Present at UBS Global Healthcare Conference

GlobeNewswire 4/16/2019 Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry D...

GlobeNewswire 3/13/2019 CORRECTING and REPLACING -- Acer Therapeutics to Participate in Upcoming Investor Conferences

ACER GDR REG.S/5 TA 10/ US0044342055 /

If you wish to receive reply to your feedback, please provide your email address.